KAP (KAP) H2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2026 earnings summary
1 Sep, 2026Executive summary
FY 2026 marked the first year of a multi-year turnaround, with disciplined execution driving improved profitability, cash generation, and returns despite challenging trading conditions and supply chain disruptions, including those from the Middle East conflict.
Net debt was reduced by ZAR 1.1 billion, more than double the initial target of ZAR 500 million.
All major divisions except Sleep Group and Optix contributed to improved performance, with PG Bison, Safripol, Unitrans, and Feltex showing notable gains.
Strategy execution established momentum for improved returns and shareholder value, with further progress required over the next 3–5 years.
Financial highlights
Revenue stable at ZAR 29.6 billion year-on-year.
EBITDA up 13% to ZAR 3.9 billion; operating profit before capital items up 28% to ZAR 2.5 billion.
Operating margin improved by 190 bps to 8.4%.
Headline earnings per share up 88% to ZAR 0.452; after impairments, a loss of ZAR 0.048 per share.
Free cash flow before dividends up 178% to ZAR 1.3 billion.
Net interest-bearing debt down 14% to ZAR 7 billion.
Outlook and guidance
Momentum expected to continue into FY 2027, but operating environment remains uncertain due to global risks, inflationary pressures, and volatile polymer prices.
Focus remains on extracting value from recent investments, addressing underperformance, and disciplined capital allocation.
Targeting further ZAR 500 million net debt reduction in FY 2027.
Unitrans medium-term operating profit target maintained at ZAR 700 million.
Latest events from KAP
- HEPS for FY26 is expected to rise by over 50%, with strong operational improvements.KAP
Trading update - EBITDA and profit rose despite lower revenue, with debt reduction and strategic focus ongoing.KAP
H1 2026 - EPS and HEPS for 1H26 are set to increase over 24% and 28% year-over-year.KAP
H1 2026 TU - Operating profit down 14% as project ramp-up and margin pressures offset revenue growth.KAP
H2 2025 - Operating profit fell 11% as Safripol lagged, but major projects and restructuring support growth.KAP
H2 2024 - Revenue up 2%, profits down on ramp-up costs; major projects complete, focus on debt reduction.KAP
H1 2025